Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Application of cultured human mast cells (CHMC) for the design and structure-activity relationship of IgE-mediated mast cell activation inhibitors.
Argade A, Bhamidipati S, Li H, Carroll D, Clough J, Keim H, Sylvain C, Rossi AB, Coquilla C, Issakani SD, Masuda ES, Payan DG, Singh R. Argade A, et al. Among authors: sylvain c. Bioorg Med Chem Lett. 2015;25(10):2117-21. doi: 10.1016/j.bmcl.2015.03.075. Epub 2015 Mar 31. Bioorg Med Chem Lett. 2015. PMID: 25872982
Design, synthesis of diaminopyrimidine inhibitors targeting IgE- and IgG-mediated activation of Fc receptor signaling.
Argade A, Bhamidipati S, Li H, Sylvain C, Clough J, Carroll D, Keim H, Braselmann S, Taylor V, Zhao H, Herlaar E, Issakani SD, Wong BR, Masuda ES, Payan DG, Singh R. Argade A, et al. Among authors: sylvain c. Bioorg Med Chem Lett. 2015;25(10):2122-8. doi: 10.1016/j.bmcl.2015.03.072. Epub 2015 Apr 1. Bioorg Med Chem Lett. 2015. PMID: 25891105
R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES. Braselmann S, et al. Among authors: sylvain c. J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008. doi: 10.1124/jpet.106.109058. Epub 2006 Aug 31. J Pharmacol Exp Ther. 2006. PMID: 16946104 Clinical Trial.
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, Ho MN, Jiang J, Kirk CJ, Laidig GJ, Lewis ER, Lu Y, Muchamuel T, Parlati F, Ring E, Shenk KD, Shields J, Shwonek PJ, Stanton T, Sun CM, Sylvain C, Woo TM, Yang J. Zhou HJ, et al. Among authors: sylvain c. J Med Chem. 2009 May 14;52(9):3028-38. doi: 10.1021/jm801329v. J Med Chem. 2009. PMID: 19348473
46 results